1. Scrip
  2. >>Business

Allergan, Ironwood Seek To Divide And Conquer IBS With New Linzess Formulations

 
• By Alexandra Shimmings

Allergan and Ironwood Pharmaceuticals are beefing up the blockbuster potential of their IBS drug Linzess with two new formulations that target different disease populations showing promising Phase II data. Further Phase IIb and III trials are now in the offing.

IBS
• Source: Shutterstock

Allergan PLC and Ironwood Pharmaceuticals Inc. have released promising topline Phase IIb data for two novel formulations of their irritable bowel syndrome (IBS) treatment Linzess (linaclotide) that they hope will boost the franchise for many years to come by offering better and faster pain relief in constipation-predominant patients and opening up the product for use in other IBS subtypes, and possibly even other GI disorders.

The two formulations, known as CR1 and CR2, are designed to deliver the drug at two separate locations in the gastrointestinal tract where they are expected to produce slightly different...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.